Table 4.
Treatment-emergent adverse events (TEAEs) with an incidence of ≥5% in either treatment group in the 12-week treatment period (all-patients-treated set)
Preferred term | Vortioxetine 10–20 mg, n (%) (n = 253) | Agomelatine 25–50 mg, n (%) (n = 242) |
---|---|---|
Patients with TEAEs | 137 (54.2) | 127 (52.5) |
Nausea | 41 (16.2) | 22 (9.1) |
Headache | 26 (10.3) | 32 (13.2) |
Dizziness | 18 (7.1) | 28 (11.6) |
Somnolence | 10 (4.0) | 19 (7.9) |